Biosulin P instructions for use
Biosulin P - a drug that is an analogue of human endogenous short-acting insulin. This insulin is obtained by genetic engineering, with the result that according to the classification Biosulin R belongs to the group of human genetically engineered insulins.
Onset of action occurs after 30-60 minutes and is observed for 6-8 hours.
Insulin receptors are found throughout the body, because it participates in almost all metabolic processes and triggers a huge number of intracellular reactions. But the main organs for insulin are the liver, muscle and adipose tissue. Biological effects of insulin:
- regulation of carbohydrate metabolism as a result of increased transport and utilization of glucose by the cells, thereby producing liver glycogen;
- inhibition of the internal synthesis of glucose due to suppression of the breakdown of liver glycogen and a decrease in the production of glucose from other sources;
- participation in the metabolism of fats, manifested by a decrease in their fat, which leads to a decrease in free blood fatty acids entering the blood;
- blocking the formation of ketones;
- increased production of fatty acids with their subsequent esterification, due to which an important coenzyme is formed in the body;
- participation in protein metabolism, which consists in increasing the transport of amino acids into cells, stimulating the production of peptides, reducing the consumption of proteins by tissues, inhibiting the formation of keto acids from amino acids.
- activation or inhibition of various types of enzymes.
Insulins are the primary means of substitution therapy in the treatment of diabetes. The choice of the drug depends on the severity and characteristics of the disease, the patient's condition and the speed and duration of the hypoglycemic effect. The treatment is carried out according to individual schemes, for which purpose insulin preparations of various duration of action are combined.
Dietary regime in the application of insulin should be limited to the energy value of food from 1700 to 3000 kcal.
When selecting the dosage, they measure the level of sugar in the blood and urine on an empty stomach and throughout the day. The final determination is subject to the reduction of hyperglycemia, glycosuria, depending on the patient's well-being.
Biosulin P is most often administered subcutaneously, less often - intramuscularly. Absorption and the time of development of the effect depends not only on the method of administration, but also on the place, amount and concentration of insulin.
Release form and composition
Biosulin P is produced in the form of a solution for injection with a dosage of 100 U / 1 ml. In the vial may be 5 ml or 10 ml; 1, 2, 3 or 5 pieces per pack. The manufacturer of the drug is Marvel LifeSciences (India).
- soluble insulin - 100 mg;
- various excipients.
The drug belongs to the group of insulin used for substitution therapy, produced by genetic engineering, subject to prescription.
Indications for use
- insulin-dependent diabetes mellitus (type I);
- insulin-independent type of diabetes mellitus (type II) with the development of resistance to oral hypoglycemic drugs;
- insulin-independent type of diabetes mellitus (type II) with the development of partial resistance to oral hypoglycemic drugs in the appointment of the combined treatment;
- intercurrent diseases (acute diseases that complicate the course of diabetes mellitus of any type);
- decompensation of carbohydrate metabolism, which is the cause of emergency in persons suffering from diabetes.
In addition, according to doctor's prescription, insulins can be used in such cases:
- in preparation for surgical procedures in persons with type II diabetes;
- diabetes in pregnant women;
- as an anabolic drug for severe exhaustion;
- with furunculosis,
- with hyperthyroidism;
- with atony or ptosis of the stomach;
- in chronic forms of hepatitis;
- in case of liver cirrhosis at the onset of the disease;
- in a state of hypoglycemic coma;
- in the treatment of acute heart failure.
Biosulin P is contraindicated:
- in case of hypersensitivity to the active substance or other components of the drug;
- in a hypoglycemic state of any origin;
- acute hepatic, pancreatic, renal diseases;
- with gastrointestinal ulcer;
- with heart defects in the stage of decompensation;
- with coronary heart failure.
Mode of application
The drug is administered 30 minutes before meals. The dosage is selected by the doctor individually.
The average amount per day is from 0.5 to 1 IU per kilogram of patient weight.
When using Biosulin P as a single agent, it is administered 3 times / day or increased to 5-6 times if necessary. At a dose of more than 0.6 IU / kg per day, it should be applied to different places in the form of 2 or more injections.
The most frequent place of introduction of Biosulin P is the abdominal wall, but it is possible to use it in the area of the buttocks, thighs, and shoulders. To prevent the development of adipose tissue dystrophy at the injection site, the injection sites need to be changed.
Intramuscular and intravenous administration is carried out only under medical supervision.
The introduction is as follows:
- using two fingers to form a skin fold;
- a needle is inserted into its base at a 45 degree angle;
- they drive subcutaneously and for a full insertion hold the needle under the skin for a few seconds, then remove it.
If blood has come out at the injection site, it is necessary to press it with a finger and hold it.
- hypoglycemia, manifested by pallor, excessive sweating, tachycardia, tremor, crawling, hunger. Increased hypoglycemia leads to hypoglycemic coma.
- redness, itching and swelling at the injection site;
- dystrophy of adipose tissue when administered in one place;
- hypersensitivity reactions in the form of rashes, angioedema, anaphylaxis is very rarely possible;
- swelling or visual impairment at the initial stage of therapy.
The causes of the hypoglycemic state can be:
- substance overdose;
- drug replacement;
- lack of food intake after drug administration;
- vomiting, diarrhea;
- increased physical activity;
- diseases in which there is a decrease in the body's need for a hormone, such as pathologies of the liver or kidneys, a decrease in the functional activity of the adrenal glands, the pituitary gland or the thyroid gland;
- interaction with other drugs.
- when changing the color of the solution, the appearance of turbidity or particles, further use is contraindicated;
- during therapy with insulin preparations, it is necessary to continuously monitor the amount of glucose in the blood;
- during long intervals between the introduction or application of improper dosage, hyperglycemia may gradually develop, which manifests itself as a sensation of thirst, frequent urination, nausea and vomiting, redness and dryness of the skin, decreased appetite and the smell of acetone from the patient. In the absence of therapy of this condition, the development of ketoacidosis, which is life-threatening, is possible;
- with increased physical exertion, infections, fever, diseases of the thyroid gland, liver, kidneys and other pathologies, as well as over 65 years of age and changes in diet, the dose of the drug needs to be adjusted;
- some diseases can increase insulin requirements (for example, various high-temperature infections);
- when changing the drug, blood glucose control is necessary;
- Biosulin P reduces the absorption of alcohol;
- The use of insulin pumps is not recommended due to the possible sedimentation of the drug in catheters.
- With various changes associated with insulin therapy, there may be a decrease in the ability to drive or perform work that requires increased attention.
- enhancing the sugar-reducing effect of Biosulin R; lithium base; alcohol-containing drugs.
- reduction of hypoglycemic effect occurs when taking hormonal contraceptives, glucocorticosteroids, thyroid hormones, some diuretics and antidepressants, heparin, sympathomimetic drugs, danazol, clonidine, antihypertensive drugs, diazoxide, narcotic analgesics, nicotine.
- Reserpine can weaken and strengthen the effect of Biosulin R.
Analogues of Biosulin P are short-acting insulins and drugs similar to them:
- Actrapid NM is available in bottles of 10 ml. Manufacturer: Novo Nordisk (Denmark). Actrapid NM Penfill from the same manufacturer, is available in a 3 ml cartridge for penfill. In packing of 5 cartridges;
- Vozulim-R also happens in the form of cartridges and vials, produced by Wockhardt Limited (India);
- Gensulin P domestic production, manufacturing company: Bioton Vostok CJSC (Russia);
- Insuman Rapid GT, Aventis Pharma Deutschland GmbH (Germany);
- Insura P is produced by the Institute of Bioorganic Chemistry. Academicians M.M. Shemyakin and Yu.A.Ovchinnikov of the Russian Academy of Sciences (Russia);
- Monoinsulin CR, Belmedpreparaty RUP (Republic of Belarus);
- Rinsulin R, GEROFARM-Bio JSC (Russia);
- Rosinsulin R, Medsintez plant (Russia);
- Humulin Regulyar, Lilly France (France).
Terms and conditions of storage
Biosulin P has a shelf life of 2 years. The storage location of the drug should be out of the reach of children and be protected from sun exposure. Storage temperature range - 2–8 degrees. Do not freeze the medicine. Use after the expiration date is prohibited.
Biosulin P price
Biosulin P injection solution 100 U / ml 10 ml - from 450 to 550 rubles.